Final Report – A Phase 4, Open-Label, Single-Arm Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba® When Administered to Immunocompromised Participants ≥10 Years of Age

Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba® When Administered to Immunocompromised Participants ≥10 Years of Age

Category & Conditions: Infections and Infectious Diseases

Medicine: TRUMENBA™(MENINGOCOCCAL GROUP B VACCINE)

ClinicalTrials.gov Identifier (NCT): NCT04893811

Protocol ID: B1971060

Print Download

Open Plain Language Summary Result: Click here